Search - tctmd.com

Displaying 1 - 17 of 17

Sort: Relevancy | Date

News Features

全年回顾：医生选出介入心脏病学等领域 2016 年的最大新闻

Shelley Wood

December 30, 2016

News Features

Year in Review: Physicians Pick the Biggest News of 2016, in Interventional Cardiology and Beyond

Shelley Wood

December 30, 2016

News Features

Repaso del Año: Los Médicos Eligen las Noticias Más Importantes de 2016 en Cardiología Intervencionista y Más

Shelley Wood

December 30, 2016

News Daily News

TAVR: Miracle for Some, but No Improvements in Quality of Life for Others

Yael L. Maxwell

December 22, 2016

News Opinion Editor's Corner TCT 2016

我对 2016 年 TCT 的总结：惊喜、假设和赠品

Shelley Wood

November 07, 2016

News Opinion Editor's Corner TCT 2016

My Takeaways From TCT 2016: Surprises, Presuppositions, and the Gift of the Giveaway

Shelley Wood

November 07, 2016

News Conference News TCT 2016

Transfemoral—but Not Transthoracic—TAVR Has Early Quality-of-Life Advantage Over Surgery in Intermediate-Risk Patients

Todd Neale

November 02, 2016

Presentation TCT 2016

Intermediate-Risk Studies I: Synthesis of the PARTNER 2A and the Sapien 3 Intermediate-Risk Trials

Presenter: Patrick T. O'Gara, Alec S. Vahanian, Susheel K. Kodali

October 30, 2016

News Daily News

New ‘Rapid Recommendations’ Tackle TAVR in Patients at Low-to-Intermediate Risk

Todd Neale

September 29, 2016

News Conference News PCR London Valves 2016

TAVR vs SAVR: Limitations and Risks Debated as Transcatheter Therapies Move Into Younger and Lower-Risk Patients

Shelley Wood

September 20, 2016

News Daily News

Sapien 3 Approved for Use in Intermediate-Risk Patients in Europe

Michael O'Riordan

September 20, 2016

News Daily News

较低风险患者 TAVR 后生存率优于手术组，没有“风险升高”

L.A. McKeown

August 24, 2016

News Daily News

Survival Better, No ‘Risk Creep’ for TAVR vs Surgery in Lower-Risk Patients

L.A. McKeown

August 24, 2016

News Daily News

Mejor Supervivencia y Ausencia de ‘Tendencia de Riesgo’ para TAVR vs Cirugía en Pacientes de Menor Riesgo

L.A. McKeown

August 24, 2016

News Daily News

大规模 Meta 分析显示，TAVR 与手术 30 天和 1 年死亡率相当

Michael O'Riordan

June 07, 2016

News Daily News

Según un Gran Meta Análisis Parecida Mortalidad al cabo de 30 Días y 1 Año con TAVR Versus Cirugía

Michael O'Riordan

June 07, 2016

News Daily News

Equivalent Mortality at 30 Days and 1 Year With TAVR vs Surgery, Says Large Meta-analysis

Michael O'Riordan

June 07, 2016

Advertisement

全年回顾：医生选出介入心脏病学等领域 2016 年的最大新闻

Year in Review: Physicians Pick the Biggest News of 2016, in Interventional Cardiology and Beyond

Repaso del Año: Los Médicos Eligen las Noticias Más Importantes de 2016 en Cardiología Intervencionista y Más

TAVR: Miracle for Some, but No Improvements in Quality of Life for Others

我对 2016 年 TCT 的总结：惊喜、假设和赠品

My Takeaways From TCT 2016: Surprises, Presuppositions, and the Gift of the Giveaway

Transfemoral—but Not Transthoracic—TAVR Has Early Quality-of-Life Advantage Over Surgery in Intermediate-Risk Patients

Intermediate-Risk Studies I: Synthesis of the PARTNER 2A and the Sapien 3 Intermediate-Risk Trials

New ‘Rapid Recommendations’ Tackle TAVR in Patients at Low-to-Intermediate Risk

TAVR vs SAVR: Limitations and Risks Debated as Transcatheter Therapies Move Into Younger and Lower-Risk Patients

Sapien 3 Approved for Use in Intermediate-Risk Patients in Europe

较低风险患者 TAVR 后生存率优于手术组，没有“风险升高”

Survival Better, No ‘Risk Creep’ for TAVR vs Surgery in Lower-Risk Patients

Mejor Supervivencia y Ausencia de ‘Tendencia de Riesgo’ para TAVR vs Cirugía en Pacientes de Menor Riesgo

大规模 Meta 分析显示，TAVR 与手术 30 天和 1 年死亡率相当

Según un Gran Meta Análisis Parecida Mortalidad al cabo de 30 Días y 1 Año con TAVR Versus Cirugía

Equivalent Mortality at 30 Days and 1 Year With TAVR vs Surgery, Says Large Meta-analysis

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content